Premium
Successful treatment of interstitial lung disease related to Stevens–Johnson syndrome/toxic epidermal necrolysis overlap with etanercept: A case report and published work review
Author(s) -
Wang Fang,
Gao Xuemei,
Chen Xiaohong,
Tang Xuhua,
Chen Haihong,
Han Jiande
Publication year - 2019
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/1346-8138.15058
Subject(s) - etanercept , toxic epidermal necrolysis , medicine , interstitial lung disease , dermatology , disease , lung , pathology , tumor necrosis factor alpha
Interstitial lung disease ( ILD ) is a rare complication of Stevens–Johnson syndrome/toxic epidermal necrolysis ( SJS / TEN ). In this study, we present the case of a 33‐year‐old woman who was diagnosed with ILD related to SJS / TEN overlap syndrome. Surprisingly, the patient did not respond to combination therapy with steroids and i.v. immunoglobulin, but rapidly improved after two doses of etanercept treatment. To our knowledge, this is the first case of SJS / TEN ‐induced ILD that was successfully treated with etanercept. We reviewed another two cases of ILD associated with SJS / TEN , and found that unlike the other cases, in the present case, ILD occurred early in the course of the disease and rapidly improved after etanercept injection. We discovered that in the present patient, the serum interleukin‐6 level increased during the progressive stage and declined after the initiation of treatment with etanercept.